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Available online - - -AbstractPancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular
diagnostic and therapeutic requirements. The specialized biochemical tests and radiological investigations, the complexity of surgical op-
tions and the variety of medical treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally
achieved through an organized network. The present study describes currents concepts in the management of these tumours as well as
an insight into the challenges of delivering the pathway in and outside a Network.
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With a European annual incidence of slightly less than
1:100 000 and comprising 8% of pancreatic tumours [1],
pancreatic neuroendocrine neoplasms (PanNENs) are
considered a very rare entity. Despite their rarity though,
they have allured remarkable scientific attention and
research resources. This is of course because rare medical
conditions require exquisite efforts from various biomed-
ical specialties, often beyond geographical limitations,
with increasing requirements in terms of time, funding
and dedication. But PanNENs also owe part of the focus
they have earned to the significantly long survival that
can be achieved, particularly compared to other tumours
of the foregut, especially of the pancreas. In a clinical
setting, patients with non-metastatic disease and
completely resected primary tumours can have a survivalthor. HPB Surgery & Liver Transplantation, Royal
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a long-term survival has been reported [2]. The rarity of
these tumours and their different biological behaviour,
which ranges from indolent to very aggressive, pose inevi-
table challenges in the diagnosis and in the treatment of
PanNENs. In this article an overview of these pathways is
presented, highlighting the difficulties encountered within
and outside a Network. A description is also provided of
the outcome of European patients with a new diagnosis
of PanNENs, during the period 2000e2007, with data
deriving from population-based cancer registries contrib-
uted to the RARECAREnet project [3].
The RARECAREnet survival data
The European burden of rare cancers was estimated by
the RARECAREnet projects [3]. Among the 198 rare tu-
mours defined by the project, four GEP NET entities
were included as clinically distinct entities. PanNENs
were 15% of all GEPNET [3]. Table 1 shows survival in
PanNENs by year since diagnosis, and 5-year relative sur-
vival by sex, age and morphology subgroup. An analysisand the European Society of Surgical Oncology. All rights reserved.
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Table 1
Survival in European patients with PanNEN tumours by sex, age and type of neuroendocrine tumour, diagnosed 2000e07 [3].
Number of cases Relative survivala 95% CI
Overall 1-year 4108 67.4% 65.9%e68.8%
3-year 4108 51.0% 49.3%e52.7%
5-year 4108 42.9% 41.0%e44.8%
Sex Male 2156 36.7% 34.2%e39.2%
Female 1952 49.6% 46.9%e52.3%
Age <24 39 66.3% 48.0%e79.4%
25e64 2449 49.0% 46.7%e51.3%
65þ 1620 31.0% 27.9%e34.0%
PanNEN type Well differentiated/non-functional 858 48.2% 44.0%e52.3%
Well differentiated/functional 331 60.1% 53.5%e66.2%
Poorly differentiated 2780 39.9% 37.7%e42.2%
Mixed 139 27.1% 18.3%e36.7%
a For sex, age and type of neuroendocrine tumour subtypes, 5-year relative survival is presented.
2 P.M. Lykoudis et al. / EJSO xx (2017) 1e7was performed of 4108 cases diagnosed during 2000e07 in
94 European countries that contributed data to the RARE-
CAREnet project [3]. Survival was 66, 49 and 41% at 1,
3 and 5 years after diagnosis respectively. Outcome was
significantly better in women than men (50% versus
37%) and reduced markedly with the increasing age.
Five-year survival rate was 66% in <25 aged patients and
reduced to 31% in patients older than 65 years. Well differ-
entiated, functioning endocrine carcinoma of pancreas
showed the best outcome, 60%. The non-functioning tu-
mours and the poorly differentiated ones showed intermedi-
ate outcome: 48% and 40%, respectively. The mixed
endocrine-exocrine carcinoma had poor 5-year survival
(27%) (see Table 2).
Diagnostic and therapeutic challenges of NEN
Classifications of PanNENs is complex. The WHO clas-
sification divides these tumours into functional (28% of all
PanNENs e Table 1) and non-functional, which comprise
about 72% of all PanNENs. PanNENs can also be classified
according to the European Neuroendocrine Tumour Society
(ENETS) (Table 3). Well differentiated tumours (also
called Low Grade or G1) are characterized by cellular
monomorphism, good differentiation, a low mitotic rate, a
Ki67 < 3% and absence of necrosis. Tumours of interme-
diate features are called G2 or Intermediate Grade with a
Ki-67 between 3% and 20%, while high Grade/G3 tumours
are characterized by cells that vary significantly in size,
shape and nuclear density, with a high mitotic rate, poor
differentiation and a Ki67 > 20% [4]. The latter comprise
now a category different from neuroendocrine carcinomas,
which are by definition poorly differentiated, but fulfil other
criteria of malignant tumours as well, as recently proposed
by the ENETS [5].
Patients with PanNENs will initially present either with
symptoms related to a functional tumour or with the space-
occupying effects caused by non-functioning tumours.
Many are found incidentally whilst imaging is performed
for non-related symptoms; a proportion of these patientsPlease cite this article in press as: Lykoudis PM, et al., Treatment challenges i
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in other organs. PanNENs can also develop in up to 80% of
patients diagnosed with Multiple Endocrine Neoplasia
(MEN) and specifically MEN1 syndrome [6]. Other famil-
ial syndromes that are associated with the development of
PanNENs are von HippeI-Lindau, Tuberosclerosis and
neurofibromatosis, with the latter being associated with
worse prognosis [7]. Serum Chromogranin A (CgA) is
the most commonly used biomarker and has been found
to correlate with prognosis [8], but its diagnostic value
was questioned during the latest revision of relevant guide-
lines issued by the National Comprehensive Cancer
Network (NCCN) [9]. The biochemical tests which are
needed to rule out a functional tumour include the hormone
that the tumour is expected to produce, such as insulin, pro-
insulin, C-peptide and anti-insulin antibodies for insulino-
mas, or glucagon, somatostatin, VIP and gastrin for the cor-
responding tumours. Recent advances include NETest,
which assesses the circulating tumour transcripts and is
shown to be associated with response to treatment with So-
matostatin analogues [10], and measurement of circulating
DNA and/or tumour cells [11] but these still need to be
validated.
Several imaging modalities play a significant role in the
diagnosis and staging process. Contrast enhanced
Computed Tomography (CT) scans with arterial and venous
phases comprise the cornerstone of investigation of pancre-
atic tumours, being the basis of current staging. However,
since PanNENs can be very small and isodense, the sensi-
tivity of this modality can be as low as 30% for primary tu-
mours [12,13]. Magnetic Resonance Imaging (MRI), with
specific sequences that enhance the accuracy for small le-
sions in the pancreas, have led to an increasing enthusiasm
in favour of this modality. A recent study demonstrated that
MRI can discriminate between Low/Intermediate tumours
and High Grade tumours, with a sensitivity of 72.3% and
a specificity of 91.6% [14]. Endoscopic Ultrasonography
(EUS) is regarded as a particularly accurate modality for
the assessment of the primary tumour as well to assess local
lymph node involvement, allowing to locate tumours andn and outside a specialist network setting: Pancreatic neuroendocrine tu-
Table 2
Most common functional PanNENs, with main symptoms, anatomical location, malignancy likelihood and incidence. (Adapted with permission from Jensen
et al., 2012[38]).
Tumour Manifestation Location Malignancy Incidence per million
Gastrinoma (Zollinger-
Ellison syndrome)
Diarrhoea, peptic ulcers 60% pancreas, 30% duodenum 60e90% 0.5e3
Insulinoma Hypoglycaemia, seizures, unconsciousness 99e100% pancreas 5e15% 1e3
Glucagonoma Migratory necrolytic rash, anaemia,
thromboembolic events
99e100% pancreas 60e80% 0.01e0.1
VIPoma Severe diarrhoea, electrolyte disorders 90% pancreas 80% 0.05e0.2
Somatostatinoma Diabetes, steatorrhoea 56% pancreas, 44% duodenum/jejunum 50e60% <0.01
GRFoma Acromegaly 30% pancreas, 54% lung, 7% jejunum 30% <0.01
ACTHoma ACTH 4e16% pancreas >90% <0.01
3P.M. Lykoudis et al. / EJSO xx (2017) 1e7obtain specimen for cytological or histological examina-
tion, with an adequacy rate of over 80% [15]. The diag-
nostic value of the method can be increased when
ultrasonographic contrast is administered, as it demon-
strated the different vascularization pattern between the
tumour and the normal pancreatic parenchyma, while it
has been suggested that it can also differentiate between
PanNENs and pancreatic adenocarcinoma [16].
A definite challenge is the availability of the best and
most accurate functional images from Nuclear Medicine
departments. Somatostatin Receptor Scintigraphy offers a
powerful differential tool for the discrimination of Pan-
NENs and other pancreatic neoplasms. Diagnostic accuracy
has been improving over the last years along with the ad-
vances in the used isotopes, with the most recent 68Ga-
DOTA-TATE, 68Ga-DOTA-1Na13, and 68Ga-DOTA-
NOC demonstrating significantly higher spatial resolution
and enhanced tumour-to-background contrast [17]. It is
evident from the above, that each modality has limitations
in terms of sensitivity and specificity (Table 4), thus
optimal diagnostic approach consists of combinations of
the aforementioned modalities (Fig. 1), with a view to iden-
tify the primary tumour, target it for biopsy, and complete
tumour staging (Table 5).
Surgery remains the cornerstone of treatment of Pan-
NENs, whether it aims to control symptoms, resect the
radiologically detectable disease, or debulk it (usually aim-
ing to remove >90% of visible disease) with a view to
improve response to further treatment. The aim of the
pancreatic endocrine surgeon is to completely resect theTable 3
ENET Classification of PanNENs according to histopathological characteristics. N
duced with permission from Falconi et al., 2012 [3]).
Biological behaviour WHO Classification (2000) WHO Classification (2010)
Benign Well-differentiated
endocrine tumour
NET G1 or NET G2
Benign or low-grade
malignant
Well-differentiated
endocrine tumour
NET G1 or NET G2
Low-grade malignant Well-differentiated
endocrine carcinoma
NET G1 or G2
High-grade malignant Poorly-differentiated
endocrine carcinoma
NEC or G3
Please cite this article in press as: Lykoudis PM, et al., Treatment challenges i
mours, Eur J Surg Oncol (2017), https://doi.org/10.1016/j.ejso.2017.08.019primary tumour with preservation of the maximum amount
of parenchyma, and thus to minimize the risk for postoper-
ative exocrine or endocrine insufficiency.
A technical challenge is the development of pancreatic
fistulas which was reported in almost 23% of patients un-
dergoing pancreatic resection for PanNENs as opposed to
17% in patients who had similar operations for other
pancreatic malignancies [18]. This higher rate can be attrib-
uted to the relative soft and friable pancreas of patients with
PanNENs, but also to the fact that enucleations are signif-
icantly more frequently performed in these patients than
in patients with other pancreatic pathologies. A recent re-
view has summarized the favourable prognostic criteria
that include age of less than 55 years, liver involvement
of less than 50%, resection of the primary tumour prior
to transplantation, stable disease for at least 6 months and
good differentiation (Ki67% < 10%), with the latter being
associated with a 5-year survival of 90% [19]. Many of
these surgical options would not be appropriate for other
malignancies and can be controversial even for the most
indolent PanNENs, suggesting that it is often the knowl-
edge of the biological behaviour and natural history of
these tumours which dictate the best therapeutic approach.
This require a dedicated panel of specialists with a specific
interest in PanNENs rarely available outside dedicated cen-
tres, which is equally crucial in the medical and radiolog-
ical management of PanNENs.
Medical treatment aims to manage symptoms, to down-
size/downstage the disease with a view to surgical resec-
tion, to manage disease progression or to palliate.ET¼Neuroendocrine tumour, NEC ¼ neuroendocrine carcinoma. (Repro-
Metastases Invasion Tumour size, cm Angio-invasion Ki67, %
e e 2 e Usually
around 2
e e >2  Usually
around 2
þ þ Any þ Usually >2
þ þ any þ >20
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Table 4
Sensitivities of Imaging modalities for PanNENs.
Modality Sensitivity
Ultrasonography 20e80%
Computed tomography 64e94%
Magnetic resonance imaging 74e100%
Endoscopic ultrasonography 80e94%
PETs 50e80%
4 P.M. Lykoudis et al. / EJSO xx (2017) 1e7Syndrome-related symptoms are managed in the acute
setting with blood glucose control in case of insulinomas
and glucagonomas, volume and electrolyte loses in VIPo-
mas, gastric pH control in gastrinomas and in all cases
with somatostatin analogues that block the somatostatin re-
ceptors and reduce secretion of active peptides.Abdomina
Abdominal C
SRS or 68G
Resectable disease
Surgery ±IOUS
Follow-up: CT/SRS
US endoscopy/hepatocyte-specific MRI
EUS(±EUS-FNAC/B)
Fig. 1. Diagnostic algorithm for the radiological investigation of PanNENs. US¼U
dle aspiration cytology/biopsy, CT¼Computed tomography, MRI ¼Magnetic Res
operative ultrasonography. (Reproduced with permission from Falconi et al., 201
Table 5
The AJCC/UICC and ENETS staging of Pancreatic Neuroendocrine Neoplasms.
Stage 0 Tis Carcinoma in situ
Stage IA T1 Tumour limited to the pancreas, 2 cm
Stage IB T2
AJCC: Tumour limited to the
pancreas, >2 cm
ENETS: Tumour l
pancreas, 2e4 cm
Stage IIA T3
AJCC: Tumour extends beyond the
pancreas, without vascular involvement
ENETS: Tumour c
>4 cm, invasion o
Stage IIB Any T
Stage III T4
AJCC: Vascular involvement ENETS: Invasion
organs or vessels
Stage IV Any T
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mours, Eur J Surg Oncol (2017), https://doi.org/10.1016/j.ejso.2017.08.019Somatostatin analogues also exert an antiproliferative role
in PanNETs, improving overall survival by delaying
tumour growth [20]. Streptozocin and fluorouracil have
been the backbone of chemotherapy regiments for many
years, with a response rate of over 60% and increase of sur-
vival by more than 1 year [21,22]. Chemotherapeutic regi-
mens vary, according to tumour features, with cisplatin and
etoposide being used for higher grade lesions [23] and te-
mozolomide with capecitabine for well differentiated tu-
mours [24]. Liposomal and conventional doxorubicin
have also been used whereas addition of the anti-
angiogenesis monoclonal antibody Bevacizumab has been
associated with a better progression free survival [25].
Recent improvements include the use of Everolimus, an
mTOR inhibitor that demonstrated increase of survival
6.3 months, though not statistically significant [26], whilel US
T/MRI
a PET
Unresectable disease
EUS or US-guided FNAC/B
ltrasonography, EUS ¼ Endoscopic Ultrasonography, FNAC/B¼Fine nee-
onance Imaging, SRS¼Somatostatin Receptors Scintigraphy, IOUS¼Intra-
2[3]).
N0 No involved
regional lymph nodes
M0 No distant
metastasis
imited to the
onfined to pancreas,
f duodenum or bile duct
N1 Regional lymph
node metastasis
Any N
of adjacent
M1 distant
metastasis
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tional benefit [27]. Another agent that has recently demon-
strated significant results is the tyrosine kinase inhibitor
Sunitinib malate, which doubled the progression free sur-
vival, and was also associated with statistically significantly
improved overall survival [28].
Several other modalities have been used to manage
neuroendocrine tumours. Radionuclide therapy is being
delivered to somatostatin receptors in an attempt for a
focused irradiation of PanNENs, either in the form of Pep-
tide Receptor Radionuclide Therapy (PRRT) or Selective
Internal Radiation Therapy (SIRT), mainly aiming to stabi-
lize the disease, with a major response rate of about 60%
and inhibition of progression in 85% [29]. Liver metastases
not amenable to surgical treatment have been managed with
hepatic artery embolization aiming for mechanical obstruc-
tion of perfusion or also local delivery of high concentra-
tion of cytotoxic agents such as streptozocin and
fluorouracil but also mitomycin C and cisplatin. This mo-
dality yields a highly successful control of symptoms of
up to 100% and a partial response that can be up to 80%
[2]. Finally, radiofrequency and microwave ablation have
also been employed with symptom control rate of >90%
and mean overall survival of 73 months [30], either in com-
bination with surgical resection, or as an alternative in pa-
tients that were not deemed fit for surgery and tumours not
amenable to surgical resection.
Medical treatment is frequently available in secondary
and tertiary institutes but complex interventional radiology
is frequently carried out in dedicated centres, especially for
procedures requiring the input of nuclear medicine special-
ists such as for SIRT or PRRT.Management within a network
Outcomes following management of any medical condi-
tion depend heavily on the expertise of healthcare delivery
team. This can be quite challenging when it comes to dis-
eases with relatively low occurrence, such as PanNENs.
In 2013, about 1500 new diagnoses of PanNENs were esti-
mated in Europe (EU28) [3]. The solution to this problem is
usually centralization of patient’s care and resources, so
that NET Units can maintain a workload that guarantees
adequate experience and enhanced outcomes. A systematic
review on upper gastrointestinal surgery, demonstrated a
clear benefit in terms of outcomes for high volume centres
and surgeons [31], whilst another study focusing particu-
larly on pancreaticoduodenectomy demonstrated improved
overall resection rates and higher R0 resection rates when
centralization was implemented [32]. Centralization has
not been studied so far specifically in PanNENs, however,
the expertise required is similar to the one required to
manage other hepato-pancreato-biliary malignancies.
Although it is extremely difficult to define a minimum
number of patients per centre, it seems reasonable toPlease cite this article in press as: Lykoudis PM, et al., Treatment challenges i
mours, Eur J Surg Oncol (2017), https://doi.org/10.1016/j.ejso.2017.08.019support that most countries would need 2e10 Units to
maintain expertise [33].
Patients with PanNENs can present with a remarkable
variety of symptoms, thus the first clinician that they see
might be a general practitioner, a family doctor, an Acci-
dent & Emergency doctor, a gastroenterologist, a general
surgeon, an endocrinologist or even a radiologist, if in lines
with the local healthcare service they can individually
arrange a radiological investigation [34]. Quite frequently,
the first working diagnosis is not this of an endocrine
tumour, thus the next steps might be advised by any of
the above specialties, as well as oncologists and hepato-
pancreato-biliary surgeons. It is of course impossible for
a PanNET Unit to exist wherever these specialists practice,
but these Units need to maintain excellent communication
and bidirectional feedback with local primary and second-
ary healthcare structures, so that an adequate level of
awareness is maintained and all physicians are familiar
with the first steps of relevant pathways.
Specific imaging investigation of PanNENs includes so-
phisticated modalities that require a certain level of radio-
logical expertise. The histopathological features of these
tumours are very specific and it is essential that involved
pathologists are explicitly familiar with this entity. Surgical
treatment of PanNENs usually involves major liver and
pancreatic surgery and in some cases liver transplantation,
which mandates management in a Hepato-Pancreato-
Biliary Unit. Endocrine management of relevant symptoms
can be very challenging and should thus be conducted by
Endocrinologists with thorough knowledge of the physi-
ology of PanNENs. Systemic treatment is evolving rapidly,
differs significantly from the systemic treatment of other
neoplasms and thus requires an Oncology team with partic-
ular interest in the management of these tumours. It be-
comes clear from the above that a GI NENs unit needs to
comprise of key medical specialties with a special interest
in these lesions. However, since pancreatic surgery is very
demanding with a significant higher mortality and
morbidity rate in low-volume centres in comparison to
high-volume centres, specific expertise is required.
Following treatment, patients with PanNENs will return
to their local community, and in many cases it might be
practically impossible for the follow-up to be carried in
the PanNEN unit that delivers treatment. It is then neces-
sary for PanNEN units to have an outreach team, consisted
of Clinical Nurse Specialists or local Primary Care practi-
tioners, than can follow patients up closely, according to
relevant guidelines, and provide feedback to relevant Units.
It becomes thus evident that the optimal treatment of pa-
tients with PanNENs requires a robust network of medical
practitioners, connecting local primary and secondary ser-
vices, with few large PanNEN Units that consult on pa-
tients’ diagnostic evaluation and treatment, and audit
current practice and outcomes. The above two-way
communication can be facilitated through regional and su-
perregional video-linked multidisciplinary meetings on an and outside a specialist network setting: Pancreatic neuroendocrine tu-
6 P.M. Lykoudis et al. / EJSO xx (2017) 1e7frequent basis. Moreover, PanNENs Units need to commu-
nicate with each other, to increase the collective experience,
to organize trials in order to delineate all grey areas, and
eventually to revise relevant guidelines.
This admirable effort does not come without costs of
course. Potentially the greatest challenge is funding.
Centralization of patients in few Units requires that these
Units are able to bear the costs of very sophisticated and
as such very expensive diagnostic and therapeutic tech-
niques. From an administrative point of view, this arrange-
ment requires a large number of staff providing office
support to both physicians and patients, facilitating
communication, data collection and maintenance, organiza-
tion of meetings and educational events. In a network that
involves many practitioners in different levels of healthcare
and often working remotely from each other, accurate
communication and documentation can be very challenging
in order to avoid confusion and teleconference infrastruc-
tures can be imperative.
Within the UK, PanNENs units are closely attached to
hepato-pancreato-biliary units, but cover is provided
beyond the existing regional referral system, in order to
tackle all the aforementioned difficulties. At European
level, the European Neuroendocrine Tumour Society
(ENETS), recognized the need for an international network
of Neuroendocrine centres in 2007, and one year later an
accreditation process began which by now has accredited
37 Centres of Excellence across Europe.
According to the Society, this effort has yielded
improved cooperation between centres and improved qual-
ity of clinical trials. The involved centres have reported
improved patient documentation, multidisciplinary team
discussions, follow-up and quality control, while the collab-
oration of Centres of Excellence has also yielded valuable
educational activities. It is without doubt difficult to quan-
tify, measure and assess the improvement in patient-related
outcomes, and the Society identifies this question as a key
point at the moment, however the current experience of
Centres of Excellence is very encouraging. The ENETS
should consider the outcome inequalities in Europe [35],
in term of outcome and consequently organization, the
latter depends of the size of the population therefore of
the expertise of clinicians and from the cancer or rare dis-
ease national programs [35]. Survival for patients with NET
from population studies largely varied across country. For
the group of GEP (including digestive system and pancreas)
well differentiated not functioning endocrine carcinoma, 5-
year survival ranged from more that 70% in the majority of
the Nordic countries and Centre of Europe (between 70 and
83%) to 60% or less in Lithuania, Latvia and Bulgaria [3].
The reason for Bulgaria was even the lack of pathological
facilities for accurately diagnosing rare neuroendocrine tu-
mours [3]. One major issue remains the quality of diag-
nosis, mainly due to inadequate facilities and abilities to
diagnose many complex rare cancers. The definition of na-
tional and international pathways for second opinions fromPlease cite this article in press as: Lykoudis PM, et al., Treatment challenges i
mours, Eur J Surg Oncol (2017), https://doi.org/10.1016/j.ejso.2017.08.019expert pathologists was also deemed important. Having this
in mind, the European Reference Networks should offer a
good opportunity to improve pathologists’ training through
dedicated training schemes and fellowships across Europe.
Cancer registration remains vital for monitoring progress in
rare cancer diagnosis and treatment for these patients.
Conclusion
Pancreatic neuroendocrine neoplasms are an entity with
particular epidemiologic and histological features, that
require complex diagnostic and treatment strategies, opti-
mally delivered by multidisciplinary teams with special in-
terest and expertise. The challenges that emerge from this
statement are best managed within a network of specialized
Units, such as the Centres of Excellence currently ac-
credited and supervised by the European Neuroendocrine
Tumour Society, with an ultimate scope to continuously
improve delivered care to patients with PanNENs.
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